Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567346 | 0.82 | LMNA (1.00) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6326029 | 0.82 | TSHR (0.65) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6328041 | 0.81 | TSHR (0.71) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6326132 | 0.81 | TP53 (0.60) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6325105 | 0.78 | S1PR1 (0.51) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL1684613 | 0.78 | TSHR (0.74) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6332720 | 0.78 | LMNA (0.73) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6327862 | 0.78 | MITF (1.00) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6327249 | 0.77 | LMNA (0.76) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL6325165 | 0.76 | TSHR (0.76) | LMNAATMMITFTP53NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | LMNA 448/4885ATM 414/4885MITF 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.